BENGALURU (Reuters) -Indian vaccine maker Bharat Biotech said on Monday it has resumed export of its COVID-19 shot, Covaxin, and has executed long-pending orders in November.
The company also said exports to additional countries will commence from December, according to a statement it shared on Twitter https://twitter.com/BharatBiotech/status/1465230047447449603?s=20.
It was not immediately clear whether or not these exports were made under the global vaccine-sharing facility COVAX.
Covaxin, which is 78% effective against severe cases of COVID-19, was approved for emergency use listing by the World Health Organization earlier this month.
It is the only homegrown vaccine being used in India’s vaccination programme, although it accounts for only about 11% of the nearly 1.23 billion doses administered so far.
India restarted on Friday exports of COVID-19 shots to COVAX for the first time since April. Serum Institute of India, the world’s biggest vaccine maker, said it was able to recommence exports as it beat its target of producing 1 billion doses of the AstraZeneca vaccine ahead of time.
(Reporting by Shivani Singh in Bengaluru;Editing by Arun Koyyur and Uttaresh.V)
